These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19174782)

  • 1. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
    Laine L; Goldkind L; Curtis SP; Connors LG; Yanqiong Z; Cannon CP
    Am J Gastroenterol; 2009 Feb; 104(2):356-62. PubMed ID: 19174782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
    Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP; Curtis SP; Bolognese JA; Laine L;
    Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS; Fuentealba C; Greenwald M; Brzezicki J; O'Brien K; Soffer B; Polis A; Bird S; Kaur A; Curtis SP;
    J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L; Curtis SP; Langman M; Jensen DM; Cryer B; Kaur A; Cannon CP
    Gastroenterology; 2008 Nov; 135(5):1517-25. PubMed ID: 18823986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P; Shell B; Cawkwell G; Li C; Ma H
    Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
    Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
    Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1240-8. PubMed ID: 20955443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
    Krum H; Swergold G; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
    J Hypertens; 2009 Apr; 27(4):886-93. PubMed ID: 19516186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
    Krum H; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
    Eur J Heart Fail; 2009 Jun; 11(6):542-50. PubMed ID: 19380329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
    Alekseeva LI
    Ter Arkh; 2010; 82(8):57-62. PubMed ID: 20873248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 19. Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective double-blinded randomized controlled trial.
    Winkler SH; Barta S; Kehl V; Schröter C; Wagner F; Grifka J; Springorum HR; Craiovan B
    Curr Med Res Opin; 2016; 32(1):37-47. PubMed ID: 26414653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X; Tian M; Zhang W; Mei H
    PLoS One; 2018; 13(1):e0190798. PubMed ID: 29320568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.